Compagnie Chargeurs Invest (CRI) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
11 Sep, 2026Executive summary
Group revenue rose 11.1% like-for-like to €374.3m in H1 2024, with recurring operating profit up 33.9% to €17.0m and EBITDA up 20.8% to €29.6m, driven by strong performances across all business lines and geographies.
Operating cashflow reached €39.6m, supporting a €32.4m reduction in net debt and a €39.7m increase in shareholders' equity, now at nearly €300m.
Net profit was -€3.4m, impacted by exceptional expenses related to restructuring and the public tender offer.
Successful public tender offer by Groupe Fribourg and partners increased their stake to 67.6%, realigning capital structure for long-term growth.
Dividend payments are expected to resume in 2025, reflecting improved operating performance.
Financial highlights
Revenue: €374.3m (+11.1% like-for-like year-over-year); EBITDA: €29.6m (+20.8%); recurring operating profit: €17.0m (+33.9%).
Gross margin improved to 26.5% (up 0.9pt year-over-year), totaling €99.3m.
Net income impacted by exceptional expenses, resulting in a net loss of €3.4m.
Operating cashflow: €39.6m (x44 vs H1 2023); net debt reduced by €32.4m to €218.7m.
Shareholders' equity at €292.1m, up €39.7m from December 2023.
Outlook and guidance
Focus for H2 2024 on improving profitability and cash generation, with continued sales momentum expected, especially in the USA and Asia.
Museum Studio targets €150m revenue for 2024, with a project pipeline valued at over €300m.
Integration of Cilander to drive new market opportunities for Chargeurs PCC.
Leverage ratio target of below 3.5x by year-end 2024.
Dividend payments anticipated to resume in 2025.
Latest events from Compagnie Chargeurs Invest
- Transformation to high-luxury focus, Novacel sale, and €14/share buyback drive strong outlook.CRI
Q2 2026 - Q1 2026 revenue fell, but strategic transformation accelerates with Novacel divestment and strong order books.CRI
Q1 2026 - Novacel sale and strategic refocus boost financial flexibility and target €1bn NAV by 2030.CRI
Q4 2025 - Strong Q3 growth in new businesses and luxury brands, with a robust outlook for 2026.CRI
Q3 2025 - Stable H1 2025 revenue and NAV growth, strong Museum Studio gains, Novacel disposal under review.CRI
Q2 2025 - Q3 2024 revenue up 11.2% year-over-year, led by Novacel and Museum Studio growth.CRI
Q3 2024 - Q1 2024 revenue up 10% as Chargeurs accelerates growth in high-value, sustainable markets.CRI
Investor Presentation - Strong growth, strategic transformation, and all resolutions passed amid market and regulatory risks.CRI
AGM 2025 - Museum Studio and Personal Goods drove 5.6% revenue growth in Q1 2025 amid global challenges.CRI
Q1 2025